Dawnzera is the first and only RNA-targeted prophylactic therapy to be approved for hereditary angioedema in adults and ...

Takeda stock steadies after early dip as FDA clears Ionis' Dawnzera for hereditary angioedema, posing fresh competition to Takeda's Takhzyro.

Good morning. The Supreme Court is allowing the Trump administration to cut $783 million in research grants tied to DEI work.

Dawnzera is the first and so far only RNA-targeting therapy approved as a prophylactic treatment for hereditary angioedema ...

The plant — which was acquired last year by Novo Nordisk and has a history of troubled inspections — was cited for having cat hair, pests, and bacteria, a recent FDA inspection showed.

Merck KGaA agreed to a deal with RNA biotech Skyhawk Therapeutics that could top out at $2 billion. Roche’s Genentech terminated a cell therapy partnership with Adaptive Biotechnologies, ending what ...

The US Food and Drug Administration (FDA) has approved Dawnzera (donidalorsen) for prophylaxis to prevent attacks of ...

Citi raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $69 from $65 and keeps a Buy rating on the shares following the FDA ...

The FDA has granted approval for Ionis Pharmaceuticals’ Dawnzera (donidalorsen), for use in preventing hereditary angioedema ...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Suzanne Aitken, SVP of managed access at Clinigen, ...

Ionis has won an FDA green light for an RNA-based hereditary angioedema (HAE) treatment, Dawnzera, that can be ...

Wall Street analysts boosted their targets on Ionis Pharmaceuticals after the FDA approved its RNA-based drug Dawnzera for ...